Halt Medical, Inc. Introduces Team to Commercialize Acessa™ System for the Treatment of Uterine Fibroids
Published: Jan 09, 2013
LIVERMORE, Calif., Jan. 9, 2013 /PRNewswire/ -- Halt Medical, Inc. introduced today a team to drive commercialization of the Acessa System, a newly FDA cleared medical device to treat uterine fibroids.
"It gives me great pleasure to introduce Rodney Marcy as our Senior Vice President of Sales and Marketing," said Jeffrey Cohen, Halt's Chief Executive Officer. "Rodney has extensive commercial experience in the medical device field, and women's health sector. This will be instrumental in our successful launch of Acessa."
Most recently, Mr. Marcy was Vice President of Sales and Marketing for venture-funded Interlace Medical, Inc. (acquired by Hologic, Inc.). He was also Director of Sales for the launch of the Gynecare Division of ETHICON, Inc., successfully introducing more than five major platform technologies in women's health. He has held senior management positions with Johnson and Johnson and Covidien.
"Acessa is the only medical device that can be used by gynecologists to treat all fibroid symptoms and types," said Mr. Marcy. "It is truly a revolutionary alternative for the millions of women with fibroids who choose to suffer with their symptoms rather than having their uterus removed. Our launch of Acessa will be led by three talented Regional Sales Directors: Larry Anderson, Tyler Holcomb, and Mike Roddick."
Russ DeLonzor, President & COO, added, "We will need to support our customers in the critical areas of reimbursement and professional education. I'm delighted to announce the following additions to the Halt Medical team: Jayne A. Little, Vice President of Global Health Economics and Reimbursement, and Nonni Letasse, R.N., Senior Director of Professional Education and Corporate Compliance."
Ms. Little was, most recently, the Vice President of Reimbursement at Optonol, Inc. (acquired by Alcon, Inc.). Ms. Little has been responsible for AMA CPT code implementation, Medicare and commercial payer coverage and policy. Joining Ms. Little's team is Sean McKinney, Region Director, Reimbursement and Healthcare Economics.
Ms. Letasse was Senior Director, Global Professional Education for Conceptus, Inc. She has over twenty years of training experience in the women's health sector. She has selected Michelle Schwinges, Professional Education Specialist, to round out her group.
Jeffrey Cohen added, "We now have FDA clearance, the capital, the product, and the team to successfully launch Acessa."
About Halt Medical, Inc.
Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. As well, the System has CE marking in the European Union and is licensed for sale in Canada. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.haltmedical.com.
SOURCE Halt Medical, Inc.